Actavis drug gets FDA panel nod to treat complicated bacterial infections

December 7, 2014 7:04 PM

15 0

An advisory panel for the US Food and Drug Administration (FDA) has approved drug maker Actavis plc for its investigational antibiotic, named ceftazidime-avibactam, for treating severe lower abdominal infections caused by the drug resistant pathogens.

Pharmaceutical company Actavis has announced that the FDA’s Anti-Infective Drugs Advisory Committee has strongly recommended ceftazidime-avibactam to treat infections like complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and acute pyelonephritis. The drugs w...

Read more

To category page